CTRS’ Owner Buyout

Dechert advised CTRS on the deal. CTRS, a French pharmaceutical company which specializes in rare diseases, executed its OBO transaction in which Mérieux Equity Partners, a...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here